Literature DB >> 24436618

Secoisolariciresinol Diglucoside (SDG) Isolated from Flaxseed, an Alternative to ACE Inhibitors in the Treatment of Hypertension.

Kailash Prasad1.   

Abstract

Secoisolariciresionol diglucoside (SDG) is a plant lignan isolated from flaxseed and is phytoestrogen. SDG is a potent and long-acting hypotensive agent. Plant phytoestrogens have inhibitory effects on angiotensin-converting enzyme (ACE). The hypotensive effects of SDG, a phytoestrogen, may be mediated through inhibition of ACE. The objective of this study was to investigate if SDG-induced hypotension is mediated through inhibition of ACE. The Sprague Dawley male rats were anesthetized and trachea was cannulated. The right jugular vein was cannulated to administer the drug and the carotid artery was cannulated to record arterial pressures using PIOEZ-1 miniature model transducer (Becton, Dickinson and Company, Franklin Lakes, NJ) and Beckman dynograph (Beckman Instruments, Inc., Schiller Park, IL). The effects of angiotensin I (0.2 µg/kg, intravenously [IV]) in the absence and presence of SDG (10 mg/kg, IV), and SDG alone on systolic, diastolic, and mean arterial pressures were measured before and after 15, 30, and 60 minutes of drug administration. SDG decreased the systolic, diastolic, and mean arterial pressure by 37, 47, and 43%, respectively, at 15 minutes and 18.8, 21.2, and 20.3%, respectively, at 60 minutes. Angiotensin I increased the arterial pressure. SDG decreased angiotensin I-induced rise in the systolic, diastolic, and mean arterial pressures by 60, 58, and 51%, respectively, at 15 minutes and 48, 46, and 30%, respectively, at 60 minutes. The data suggest that SDG reduced the angiotensin I-induced rise in the arterial pressures and hence SDG is a potent ACE inhibitor.

Entities:  

Keywords:  angiotensin I; angiotensin-converting enzyme inhibitor; arterial pressures; flaxseed; secoisolariciresinol diglucoside

Year:  2013        PMID: 24436618      PMCID: PMC3830572          DOI: 10.1055/s-0033-1351687

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  11 in total

Review 1.  ACE inhibitors in the treatment of hypertension in the older patient.

Authors:  D Canter; G Frank
Journal:  Eur Heart J       Date:  1990-05       Impact factor: 29.983

Review 2.  Angiotensin-converting enzyme inhibitors.

Authors:  N J Brown; D E Vaughan
Journal:  Circulation       Date:  1998-04-14       Impact factor: 29.690

Review 3.  ACE inhibitors versus AT1 blockers in the treatment of hypertension and syndrome X.

Authors:  R Feldman
Journal:  Can J Cardiol       Date:  2000-08       Impact factor: 5.223

4.  Effect of the angiotensin-converting enzyme inhibitor, captopril, on development of renal hypertension in rats.

Authors:  M J Fregly; O E Lockley; C E Simpson
Journal:  Pharmacology       Date:  1981       Impact factor: 2.547

5.  Renal vasodilatation caused by captopril in conscious normotensive and Goldblatt hypertensive dogs.

Authors:  B G Zimmerman; C Mommsen; E Kraft
Journal:  Proc Soc Exp Biol Med       Date:  1980-09

Review 6.  ACE inhibitors for the treatment of hypertension drug selection by means of the SOJA method.

Authors:  Lesley Edgar; Anita Hogg; Mike Scott; Mark Timoney; James Mc Elnay; Jill Mairs; Robert Janknegt
Journal:  Rev Recent Clin Trials       Date:  2011-01

7.  Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women.

Authors:  S Washburn; G L Burke; T Morgan; M Anthony
Journal:  Menopause       Date:  1999       Impact factor: 2.953

8.  Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed.

Authors:  K Prasad
Journal:  Circulation       Date:  1999-03-16       Impact factor: 29.690

9.  Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.

Authors:  D M Gross; C S Sweet; E H Ulm; E P Backlund; A A Morris; D Weitz; D L Bohn; H C Wenger; T C Vassil; C A Stone
Journal:  J Pharmacol Exp Ther       Date:  1981-03       Impact factor: 4.030

10.  Chemical studies of phytoestrogens and related compounds in dietary supplements: flax and chaparral.

Authors:  W R Obermeyer; S M Musser; J M Betz; R E Casey; A E Pohland; S W Page
Journal:  Proc Soc Exp Biol Med       Date:  1995-01
View more
  7 in total

1.  Secoisolariciresinol diglucoside in high-fat diet and streptozotocin-induced diabetic nephropathy in rats: a possible renoprotective effect.

Authors:  Iman O Sherif
Journal:  J Physiol Biochem       Date:  2014-10-15       Impact factor: 4.158

Review 2.  Flaxseed for hypertension: implications for blood pressure regulation.

Authors:  Stephanie P B Caligiuri; Andrea L Edel; Michel Aliani; Grant N Pierce
Journal:  Curr Hypertens Rep       Date:  2014-12       Impact factor: 5.369

3.  Comparing Flaxseed and Perindopril in the Prevention of Doxorubicin and Trastuzumab-Induced Cardiotoxicity in C57Bl/6 Mice.

Authors:  Cameron R Eekhoudt; Tessa Bortoluzzi; Sonu S Varghese; David Y C Cheung; Simon Christie; Skyler Eastman; Ishika Mittal; J Alejandro Austria; Harold M Aukema; Amir Ravandi; James Thliveris; Pawan K Singal; Davinder S Jassal
Journal:  Curr Oncol       Date:  2022-04-21       Impact factor: 3.109

4.  Protocol for a 24-Week Randomized Controlled Study of Once-Daily Oral Dose of Flax Lignan to Healthy Older Adults.

Authors:  Jane Alcorn; Susan Whiting; Navita Viveky; Yunyun Di; Kerry Mansell; Sharyle Fowler; Lilian Thorpe; Ahmed Almousa; Pui Chi Cheng; Jennifer Jones; Jennifer Billinsky; Thomas Hadjistavropoulos
Journal:  JMIR Res Protoc       Date:  2017-02-03

5.  Combination therapy of flaxseed and hesperidin enhances the effectiveness of lifestyle modification in cardiovascular risk control in prediabetes: a randomized controlled trial.

Authors:  Zahra Yari; Zahra Naser-Nakhaee; Elahe Karimi-Shahrbabak; Makan Cheraghpour; Mehdi Hedayati; Seyede Marjan Mohaghegh; Shahrzad Ommi; Azita Hekmatdoost
Journal:  Diabetol Metab Syndr       Date:  2021-01-06       Impact factor: 3.320

Review 6.  Evaluation of botanicals as potential COVID-19 symptoms terminator.

Authors:  Ufuk Koca Caliskan; Methiye Mancak Karakus
Journal:  World J Gastroenterol       Date:  2021-10-21       Impact factor: 5.374

7.  Secoisolariciresinol Diglucoside Delays the Progression of Aging-Related Diseases and Extends the Lifespan of Caenorhabditis elegans via DAF-16 and HSF-1.

Authors:  Min Lu; Lin Tan; Xiao-Gang Zhou; Zhong-Lin Yang; Qing Zhu; Jian-Ning Chen; Huai-Rong Luo; Gui-Sheng Wu
Journal:  Oxid Med Cell Longev       Date:  2020-07-14       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.